Use of Tinzaparin for Anticoagulation in Hemodialysis
Launched by CHRISTINE RIBIC · Aug 27, 2013
Trial Information
Current as of May 18, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>= 18 years
- • End stage renal disease maintained on outpatient hemodialysis for \>= 3 months
- • Frequency of hemodialysis: 3 times per week
- • Anticoagulation with an unfractionated heparin protocol for at least 4 weeks
- • Patient or legal guardian able to provide written consent
- • Baseline INR \<= 1.3
- • Baseline platelet count \>= 80,000 x 10\^9/L
- Exclusion Criteria:
- • Therapeutic systemic anticoagulation
- • Clinically apparent bleeding in the last 2 months
- • High risk of bleeding
- • Planned major surgery in the next 4 months
- • Major surgery in the past 48 hours
- • Pregnant or lactating
- • Child bearing potential
- • Allergy/intolerance to heparin or history of heparin induced thrombocytopenia
- • Current participation in a related randomized drug trial
About Christine Ribic
Christine Ribic is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative trial design and execution. With a strong focus on oncology and personalized medicine, she leads a team that collaborates with leading healthcare institutions and researchers to ensure rigorous adherence to regulatory standards and ethical practices. Christine Ribic's expertise in trial management and her passion for patient-centric approaches drive the development of novel therapies, ultimately aiming to enhance treatment options and quality of life for patients facing complex health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamilton, Ontario, Canada
Patients applied
Trial Officials
Dr. Christine M Ribic, MD, MSc
Principal Investigator
St. Joseph's Healthcare Hamilton/McMaster University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials